Reasons to Retain Cooper Companies Stock in Your Portfolio for Now

The Cooper Companies (COO) is positioned for long-term growth, driven by CooperVision's premium MyDay lens migration and the multi-billion dollar MiSight myopia management opportunity, alongside its expanding CooperSurgical fertility and women's health portfolio. However, the company faces significant near-term headwinds, including channel inventory volatility from the clariti-to-MyDay transition, a 20% decline in China e-commerce sales, and tariff/FX pressures, which have contributed to a 27.5% year-to-date stock underperformance. Despite these operational challenges, analysts project a 9.3% bottom-line improvement over five years and solid FY25 revenue and EPS growth, indicating a mixed outlook for the Zacks Rank #3 (Hold) company.

Analysis

The Cooper Companies (COO) presents a duality of strong long-term growth prospects countered by significant near-term operational headwinds. The company's core CooperVision segment is driving a strategic shift from lower-margin clariti lenses to its premium MyDay silicone hydrogel family, which is experiencing double-digit growth and aims to enhance margins. This is complemented by the formidable opportunity presented by MiSight, the sole FDA-approved lens for slowing myopia progression, positioning COO to capitalize on a market projected to affect half the global population by 2050. Further revenue diversification is provided by the CooperSurgical division, which is benefiting from rising IVF demand and an expanding portfolio in women's health. However, these positive drivers are currently overshadowed by considerable challenges that have contributed to the stock's 27.5% year-to-date decline. The transition to MyDay has created near-term revenue volatility, pulling third-quarter organic growth down to almost 2% as clariti orders fell faster than anticipated. Furthermore, significant weakness in the Asia-Pacific region, highlighted by a 20% decline in China's e-commerce sales, poses a structural risk to growth targets. The outlook is further clouded by macroeconomic factors, including an expected $4 million tariff impact on FY25 cost of goods sold and a potential 3% EPS headwind in FY26, which could pressure margin resilience. Despite these issues, the company has a track record of beating earnings estimates and consensus forecasts point to 5.1% revenue and 10.8% adjusted EPS growth for fiscal 2025, reflecting a complex scenario where long-term strategy is at odds with current performance.

Key Decisions for Investors

• Investors should closely monitor the execution of the clariti-to-MyDay product transition, as stabilization in organic growth and margin improvement will be critical validation points for the company's long-term strategy.
• The 20% decline in China's e-commerce sales represents a significant headwind, and it is crucial to watch for any changes in the company's regional strategy and its ability to regain momentum without sacrificing margins.
• While the stock's 27.5% year-to-date underperformance may seem attractive, the identified near-term revenue volatility, execution risks, and APAC weakness suggest a cautious stance is warranted until there is clearer evidence of a turnaround.
• Factor the specific financial headwinds, including the projected $4 million tariff impact for fiscal 2025 and a potential 3% EPS drag in fiscal 2026, into valuation models to accurately assess future profitability.